Community Academic Profiles–

Robert Harrington

Back to Profile

Publication Details

  • Platelet inhibition with cangrelor in patients undergoing PCI.

    Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. N Engl J Med. 2009; 361 (24): 2318-29

    Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an intravenous blocker of the adenosine diphosphate receptor P2Y(12). This agent might have a role in the treatment of patients who require rapid, predictable, and profound but reversible platelet inhibition.

    PubMedID: 19915221

Stanford Medicine Resources:

Footer Links: